T. Rowe Price Associates
AVIR icon

T. Rowe Price Associates’s Atea Pharmaceuticals AVIR Stock Holding History

T. Rowe Price Associates’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$539K Buy
115,808
+9,246
+9% +$46K ﹤0.01% 2599
2026
Q1 		$574K Buy
106,562
+9,242
+9% +$42.4K ﹤0.01% 2387
2025
Q4 		$348K Sell
97,320
-213
-0.2% -$677 ﹤0.01% 2567
2025
Q3 		$283K Buy
97,533
+17,623
+22% +$60.2K ﹤0.01% 2627
2025
Q2 		$288K Hold
79,910
– – ﹤0.01% 2549
2025
Q1 		$239K Buy
79,910
+6,027
+8% +$18.8K ﹤0.01% 2559
2024
Q4 		$248K Buy
73,883
+3,882
+6% +$12.9K ﹤0.01% 2596
2024
Q3 		$235K Buy
70,001
+3,341
+5% +$12.1K ﹤0.01% 2589
2024
Q2 		$221K Sell
66,660
-477
-0.7% -$1.78K ﹤0.01% 2555
2024
Q1 		$272K Buy
67,137
+11,968
+22% +$46.8K ﹤0.01% 2477
2023
Q4 		$169K Buy
55,169
+12,927
+31% +$39.1K ﹤0.01% 2599
2023
Q3 		$127K Buy
42,242
+1,010
+2% +$3.44K ﹤0.01% 2618
2023
Q2 		$155K Buy
41,232
+1,488
+4% +$5.57K ﹤0.01% 2596
2023
Q1 		$134K Buy
39,744
+10,931
+38% +$44.3K ﹤0.01% 2624
2022
Q4 		$139K Buy
28,813
+1,192
+4% +$6.03K ﹤0.01% 2641
2022
Q3 		$158K Buy
27,621
+4,540
+20% +$34.8K ﹤0.01% 2616
2022
Q2 		$164K Sell
23,081
-422,879
-95% -$2.89M ﹤0.01% 2649
2022
Q1 		$3.22M Buy
445,960
+33,045
+8% +$224K ﹤0.01% 1558
2021
Q4 		$3.69M Sell
412,915
-1,083,050
-72% -$16.9M ﹤0.01% 1543
2021
Q3 		$52.4M Sell
1,495,965
-195,517
-12% -$5.42M ﹤0.01% 989
2021
Q2 		$36.3M Sell
1,691,482
-869,893
-34% -$26.1M ﹤0.01% 1137
2021
Q1 		$154M Buy
2,561,375
+43,398
+2% +$2.93M 0.02% 635
2020
Q4 		$102M Buy
+2,517,977
New +$81.2M 0.01% 721

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

T. Rowe Price Associates's AVIR Position: Q2 2026 in Review

T. Rowe Price Associates increased its Atea Pharmaceuticals (AVIR) stake by 8.7% in Q2 2026, buying an estimated $46K and bringing the position to 115,808 shares worth $539K. The position accounts for ﹤0.01% of the portfolio, ranked #2599.

T. Rowe Price Associates first reported a position in AVIR in Q4 2020 and has held it in 23 quarters since. The position peaked at $154M in Q1 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • T. Rowe Price Associates held 115,808 shares of Atea Pharmaceuticals worth $539K as of Q2 2026.
  • T. Rowe Price Associates bought 9,246 Atea Pharmaceuticals shares in Q2 2026, an estimated $46K.
  • Atea Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2599 holding.
  • T. Rowe Price Associates first reported a position in Atea Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • T. Rowe Price Associates's Atea Pharmaceuticals position peaked at $154M in Q1 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.